Vividion Therapeutics

OverviewSuggest Edit

Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s cutting-edge platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.


Latest Updates

Cybersecurity ratingBMore

Key People/Management at Vividion Therapeutics

Bob Abraham

Bob Abraham

Chief Science Officer
Jeff Hatfield

Jeff Hatfield

Chief Executive Officer and Director
Robert Abraham

Robert Abraham

Chief Science Officer
Patty Allen

Patty Allen

Chief Financial Officer
Show more

Vividion Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Vividion Therapeutics total Funding

$236.5 m

Vividion Therapeutics latest funding size

$82 m

Time since last funding

2 years ago

Vividion Therapeutics investors

Vividion Therapeutics's latest funding round in April 2019 was reported to be $82 m. In total, Vividion Therapeutics has raised $236.5 m
Show all financial metrics

Vividion Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Vividion Therapeutics Online and Social Media Presence

Embed Graph

Vividion Therapeutics News and Updates

Bayer to Buy Vividion Therapeutics for Up to $2 Billion

Bayer to Buy Vividion Therapeutics for Up to $2 Billion

Vividion Therapeutics Expands Leadership Team with the Appointments of Fred Aslan, M.D., President and Chief Business Officer, and Larry Burgess, Ph.D., Head of Chemistry

SAN DIEGO, Sept. 25, 2018 /PRNewswire/ -- Vividion Therapeutics, a biotechnology company applying revolutionary proteomics and chemistry platforms to discover and develop novel small molecule therapeutics, today announced the appointments of Fred Aslan, M.D. as President and Chief...

Vividion Therapeutics Frequently Asked Questions

  • When was Vividion Therapeutics founded?

    Vividion Therapeutics was founded in 2013.

  • Who are Vividion Therapeutics key executives?

    Vividion Therapeutics's key executives are Bob Abraham, Jeff Hatfield and Robert Abraham.

  • Who are Vividion Therapeutics competitors?

    Competitors of Vividion Therapeutics include Plasma Industries, Serum Institute of India and Bio Farma.